SIRION LentiBOOST™ non-cytotoxic transduction enhancer for lentiviral vectors

SIRION Biotech has developed LentiBOOST^™ as a highly effective, non-cytotoxic transduction enhancer for lentiviral vectors in preclinical and clinical applications.

As a universally acting and receptor independent adjuvant, LentiBOOST^™ can be applied to a wide range of clinically relevant cell types, making it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

With up to five-fold increases in transduction, LentiBOOST offers powerful benefits for biotech and pharma companies, drug developers, academic researchers seeking improved results in CAR-T clinical trials, cell therapy research and development studies.

LentiBOOST^™ features

LentiBOOST^™ is a highly effective, non-cytotoxic transduction enhancer for preclinical and clinical application of lentiviral vectors. As universally acting (receptor independent) adjuvant it can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells and NK cells.

These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.

LentiBOOST^™ features include:

• Shows up to 90% improvements in lentiviral transduction efficiency.
• Positive impact on cell proliferation for CD34+ and T cells.
• Non-cytotoxic.
• Increased vector copy numbers per cell.
• Successful track record of integration into clinical trials (III and I/II) in the US and Europe.
• GMP batch grades available.

LentiBOOST^™ benefits

LentiBOOST’s powerful features and advantages deliver a series of user benefits:

• Increased expression levels of therapeutic protein have favorable effects on success rates of clinical trials.
• Better-optimized and more stable transgenic cell manufacturing allows reduced cost of final product.
• LentiBOOST^™ exhibits strong and durable therapeutic protein expression, in line with FDA/EMA criteria for ATMPs production.
• Proven lack of cell toxicity and prior clinical applications expedite IND filings.
• Availability of cGMP batch grades allow direct integration into clinical programs.

LentiBOOST variants

LentiBOOST^™ is available in two versions:

• LentiBOOST^™ Pharma grade: intended for use in preclinical research and process development only.
• LentiBOOST^™ GMP grade: for use in clinical stage protocols, currently included in multiple Phase III and I/II clinical trials in Europe and North America.

Contacts

For quotes and detailed information on LentiBOOST™ technology, contact: [email protected].
For licensing options for Clinical/Commercial Use and Development, contact: [email protected].

Resources

Click on LentiBOOST Transduction Enhancer for detailed information.